Skip to main content
Top

Distinct Challenges of Eruptive and Non-Eruptive Calcified Nodules in Percutaneous Coronary Intervention

Published in:

Abstract

Purpose of Review

To provide a summary of prevalence, pathogenesis, and treatment of coronary calcified nodules (CNs).

Recent Findings

CNs are most frequently detected at the sites of hinge motion of severely calcified lesions such as in the middle segment of right coronary artery and left main coronary bifurcation. On histopathology, CNs exhibit two distinctive morphologies: eruptive and non-eruptive. Eruptive CNs, which have a disrupted fibrous cap with adherent thrombi, are biologically active. Non-eruptive CNs, which have an intact fibrous cap without thrombi, are biologically inactive, representing either healed eruptive CNs or protrusion of calcium due to plaque progression. Recent studies using optical coherence tomography (OCT) have shown a difference in the mechanism of stent failure in the two subtypes, demonstrating early reappearance of eruptive CNs in the stent (at ~ 6 months) as a unique mechanism of stent failure that does not seem to be preventable by simply achieving adequate stent expansion. The cause of CN reappearance in stent is not known and could be due to acute or subacute intrusion or continued growth of the CN. Whether modification of CN is needed, the most effective calcium modification modality and effectiveness of stent implantation in eruptive CNs has not been elucidated.

Summary

In this review, we discuss pathogenesis of CNs and how intravascular imaging can help diagnose and manage patients with CNs. We also discuss medical and transcatheter therapies beyond conventional stent implantation for effective treatment of eruptive CNs that warrant testing in prospective studies.
Title
Distinct Challenges of Eruptive and Non-Eruptive Calcified Nodules in Percutaneous Coronary Intervention
Authors
Keyvan Karimi Galougahi
Doosup Shin
Ali Dakroub
Koshiro Sakai
Mandeep Singh
Sarah Malik
Akiko Maehara
Mitsuaki Matsumura
Gary Mintz
James C. Spratt
Omar Khalique
Evan Shlofmitz
Allen Jeremias
Richard Shlofmitz
Ziad A. Ali
Publication date
29-05-2024
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 7/2024
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02075-w
This content is only visible if you are logged in and have the appropriate permissions.

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME